UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines for the welfare and use of animals in cancer research

British journal of cancer, 2010-05, Vol.102 (11), p.1555-1577

2010

Volltextzugriff (PDF)

Vascular‐targeting therapies for treatment of malignant disease

Cancer, 2004-06, Vol.100 (12), p.2491-2499

2004

Volltextzugriff (PDF)

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

The Journal of clinical investigation, 2005-11, Vol.115 (11), p.2992-3006

2005

Volltextzugriff (PDF)

Combretastatin A4 phosphate: background and current clinical status

Expert opinion on investigational drugs, 2004-09, Vol.13 (9), p.1171-1182

2004

Volltextzugriff (PDF)

The development of combretastatin A4 phosphate as a vascular targeting agent

International journal of radiation oncology, biology, physics, 2002-12, Vol.54 (5), p.1491-1496

2002

Volltextzugriff (PDF)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate : Intravital microscopy and measurement of vascular permeability

Cancer research (Chicago, Ill.), 2001-09, Vol.61 (17), p.6413-6422

2001

Volltextzugriff (PDF)

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (24), p.7247-7253

2002

Volltextzugriff (PDF)

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

Cancer research (Chicago, Ill.), 1997-05, Vol.57 (10), p.1829-1834

1997

Volltextzugriff (PDF)

Combretastatin A-4 phosphate as a tumor vascular-targeting agent : Early effects in tumors and normal tissues

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (7), p.1626-1634

1999

Volltextzugriff (PDF)

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

Anticancer research, 1999-01, Vol.19 (1A), p.189

1999

Volltextzugriff (PDF)

Tumour vasculature as a target for cancer therapy

British journal of cancer, 1999-07, Vol.80 Suppl 1, p.57-64

1999

Volltextzugriff (PDF)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

Anticancer research, 2001-01, Vol.21 (1A), p.93

2001

Volltextzugriff (PDF)

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

International journal of cancer, 2004-09, Vol.111 (4), p.604-610

2004

Volltextzugriff (PDF)

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

British Journal of Cancer, 1999-05, Vol.80 (5-6), p.724-732

1999

Volltextzugriff (PDF)

Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4

Cancer research (Chicago, Ill.), 1998-10, Vol.58 (20), p.4510-4514

1998

Volltextzugriff (PDF)

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy

British journal of cancer, 2000-06, Vol.82 (11), p.1835-1843

2000

Volltextzugriff (PDF)

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate

Cancer research (Chicago, Ill.), 2001-06, Vol.61 (12), p.4716-4722

2001

Volltextzugriff (PDF)

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability

Cancer research (Chicago, Ill.), 2001-09, Vol.61 (18), p.6811-6815

2001

Volltextzugriff (PDF)

Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy

British journal of cancer, 2001-02, Vol.84 (4), p.565-570

2001

Volltextzugriff (PDF)

Tumour blood flow changes induced by application of electric pulses

European journal of cancer (1990), 1999-04, Vol.35 (4), p.672-677

1999

Volltextzugriff (PDF)

Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents

British journal of cancer. Supplement, 1996-07, Vol.27, p.S86-S88

1996

Volltextzugriff (PDF)

Tumor blood flow modifying effect of electrochemotherapy with bleomycin

Anticancer research, 1999-09, Vol.19 (5B), p.4017

1999

Volltextzugriff (PDF)

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate

Anticancer research, 2003-03, Vol.23 (2B), p.1433

2003

Volltextzugriff (PDF)

Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503

Anticancer research, 2002-05, Vol.22 (3), p.1453

2002

Volltextzugriff (PDF)

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

British journal of cancer, 1998-06, Vol.77 (11), p.1761-1767

1998

Volltextzugriff (PDF)

1 – 25 von 164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(163)
Buchkapitel
(1)

Sprache

Englisch
(164)

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(149)
Animals
(126)
Oncology
(112)
Mice
(100)
Biological And Medical Sciences
(95)
Medical Sciences
(88)
Female
(68)
Tumors
(46)
Radiology, Nuclear Medicine & Medical Imaging
(44)
Humans
(43)
Pharmacology. Drug Treatments
(41)
Antineoplastic Agents
(39)
Mice, Inbred C3h
(37)
Neoplasms, Experimental - Blood Supply
(30)
Neoplasm Transplantation
(28)
Mice, Inbred Cba
(27)
Male
(24)
Chemotherapy
(23)
Cell Survival - Drug Effects
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Guidelines for the welfare and use of animals in cancer research

Vascular‐targeting therapies for treatment of malignant disease

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

Combretastatin A4 phosphate: background and current clinical status

The development of combretastatin A4 phosphate as a vascular targeting agent

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate : Intravital microscopy and measurement of vascular permeability

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

Combretastatin A-4 phosphate as a tumor vascular-targeting agent : Early effects in tumors and normal tissues

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

Tumour vasculature as a target for cancer therapy

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability

Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy

Tumour blood flow changes induced by application of electric pulses

Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents

Tumor blood flow modifying effect of electrochemotherapy with bleomycin

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate

Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

Suchergebnisse filtern